Compare ABG & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABG | XENE |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | 2001 | 2014 |
| Metric | ABG | XENE |
|---|---|---|
| Price | $196.29 | $56.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $252.17 | $67.17 |
| AVG Volume (30 Days) | 192.0K | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.88 | N/A |
| EPS | ★ 25.13 | N/A |
| Revenue | ★ $17,999,000,000.00 | $311,000.00 |
| Revenue This Year | $5.98 | N/A |
| Revenue Next Year | $2.22 | $2,436.26 |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $184.61 | $26.74 |
| 52 Week High | $274.50 | $62.91 |
| Indicator | ABG | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 62.01 |
| Support Level | $184.61 | $39.93 |
| Resistance Level | $199.99 | $62.91 |
| Average True Range (ATR) | 5.51 | 1.87 |
| MACD | 1.77 | -0.23 |
| Stochastic Oscillator | 78.58 | 63.35 |
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 171 new-vehicle stores and 39 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 15 states (mostly in Rocky Mountain states, Texas, the Northeast, and Southeast). Asbury store brands include Herb Chambers in the Northeast, McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated about $18 billion of revenue in 2025 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.